Evidence map›Paper›PMID 34541432›Full record

ArticlePathogens & immunity2021

Generation of a Novel SARS-CoV-2 Sub-genomic RNA Due to the R203K/G204R Variant in Nucleocapsid: Homologous Recombination has Potential to Change SARS-CoV-2 at Both Protein and RNA Level.

Shay Leary, Silvana Gaudieri, Matthew D Parker, Abha Chopra, Ian James, Suman Pakala, Eric Alves, Mina John, Benjamin B Lindsey, Alexander J Keeley and 11 more

Open access · diamondAbstract read
In one paragraph

Article in Pathogens & immunity, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed
3.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 66 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Assembly of SARS-CoV-2 ribonucleosomes by truncated NThe Journal of biological chemistry · 2023
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors at 8 institutions in 3 countries.

Shay LearyInstitute for Immunology and Infectious Diseases, Murdoch University, Murdoch, Western Australia, Australia.
Silvana GaudieriInstitute for Immunology and Infectious Diseases, Murdoch University, Murdoch, Western Australia, Australia.
Matthew D ParkerSheffield Biomedical Research Centre, Sheffield Bioinformatics Core, The University of Sheffield, Sheffield, United Kingdom.
Abha ChopraInstitute for Immunology and Infectious Diseases, Murdoch University, Murdoch, Western Australia, Australia.
Ian JamesInstitute for Immunology and Infectious Diseases, Murdoch University, Murdoch, Western Australia, Australia.
Suman PakalaDivision of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, United States.
Eric AlvesSchool of Human Sciences, University of Western Australia, Crawley, Western Australia, Australia.
Mina JohnInstitute for Immunology and Infectious Diseases, Murdoch University, Murdoch, Western Australia, Australia.
Benjamin B LindseySheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom.
Alexander J KeeleySheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom.
Sarah L Rowland-JonesSheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom.
Maurice S SwansonDepartment of Molecular Genetics and Microbiology, Center for NeuroGenetics and the Genetics Institute, University of Florida, Gainesville, Florida, United States.
David A OstrovDepartment of Pathology, Immunology and Laboratory Medicine, University of Florida, Gainesville, Florida, United States.
Jodi L BubenikDepartment of Molecular Genetics and Microbiology, Center for NeuroGenetics and the Genetics Institute, University of Florida, Gainesville, Florida, United States.
Suman R DasDivision of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, United States.
John SidneyCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, California, United States.
Alessandro SetteCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, California, United States.
COVID-19 Genomics UK (COG-UK) consortium
Thushan I de SilvaSheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom.
Elizabeth PhillipsInstitute for Immunology and Infectious Diseases, Murdoch University, Murdoch, Western Australia, Australia.
Simon MallalInstitute for Immunology and Infectious Diseases, Murdoch University, Murdoch, Western Australia, Australia.
Murdoch University · AUUniversity of Florida · USUniversity of Sheffield · GBVanderbilt University Medical Center · USLa Jolla Institute for Immunology · USSheffield Teaching Hospitals NHS Foundation Trust · GBRoyal Perth Hospital · AUUniversity of Western Australia · AU

Funding

Medical Research Council MC_PC_19027
6 · The paper itself

Abstract

backgroundGenetic variations across the SARS-CoV-2 genome may influence transmissibility of the virus and the host's anti-viral immune response, in turn affecting the frequency of variants over time. In this study, we examined the adjacent amino acid polymorphisms in the nucleocapsid (R203K/G204R) of SARS-CoV-2 that arose on the background of the spike D614G change and describe how strains harboring these changes became dominant circulating strains globally.

methodsDeep-sequencing data of SARS-CoV-2 from public databases and from clinical samples were analyzed to identify and map genetic variants and sub-genomic RNA transcripts across the genome. Results: Sequence analysis suggests that the 3 adjacent nucleotide changes that result in the K203/R204 variant have arisen by homologous recombination from the core sequence of the leader transcription-regulating sequence (TRS) rather than by stepwise mutation. The resulting sequence changes generate a novel sub-genomic RNA transcript for the C-terminal dimerization domain of nucleocapsid. Deep-sequencing data from 981 clinical samples confirmed the presence of the novel TRS-CS-dimerization domain RNA in individuals with the K203/R204 variant. Quantification of sub-genomic RNA indicates that viruses with the K203/R204 variant may also have increased expression of sub-genomic RNA from other open reading frames.

conclusionsThe finding that homologous recombination from the TRS may have occurred since the introduction of SARS-CoV-2 in humans, resulting in both coding changes and novel sub-genomic RNA transcripts, suggests this as a mechanism for diversification and adaptation within its new host.

Indexed as

COVID-19homologous recombinationSARS-CoV-2sub-genomic RNA transcripttranscription-regulating sequenceviral polymorphism

Identifiers

PMID34541432
PMCPMC8439434
OpenAlexW3194831016

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.